High Alert
Absorption: Well absorbed following oral administration; food significantly enhances absorption.
Distribution: Extensively distributed to tissues.
Protein Binding: >99.7%.
Half-Life: Cometriq:55 hr; Cabometyx:99 hr.
Contraindicated in:
Use Cautiously in:
CV: hypertension, THROMBOTIC EVENTS
Derm: dry skin, hair color changes, palmar-plantar erythrodysesthesia, rash, impaired wound healing
Endo: hypothyroidism, ADRENAL INSUFFICIENCY (IN COMBINATION WITH NIVOLUMAB)
F and E: hypocalcemia, hypophosphatemia, hypokalemia, hypomagnesemia, hyponatremia
GI: abdominal pain, altered taste, ↓appetite, constipation, diarrhea, dyspepsia, hepatotoxicity(in combination with nivolumab), ↑liver enzymes, nausea, oral pain, stomatitis, vomiting, weight loss, GI PERFORATION/FISTULA
GU: proteinuria, infertility, nephrotic syndrome
Hemat: lymphocytopenia, neutropenia, thrombocytopenia, anemia, BLEEDING
MS: arthralgia, muscle spasms, osteonecrosis of the jaw
Neuro: dizziness, fatigue, headache, POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES)
Drug-drug:
Drug-Natural Products:
Drug-Food:
Cabometyx
Hepatic Impairment
Hepatic Impairment
Hepatic Impairment
Hepatic Impairment
Cometriq
Hepatic Impairment
Lab Test Considerations: